Unlike most products offered in the market today which only provide temporary symptom relief for sinus infections, NOTA has identified a novel approach using natural therapeutic agents to specifically target bacteria biofilm.

Leveraging patented technologies developed in conjunction with the University of Michigan, NOTA Laboratories has developed a treatment for chronic rhinosinusitis (CRS) that uses safe chemical approaches to induce increased nitric oxide production in the sinus airways, thus restoring an important antimicrobial and antiviral equilibrium to fight infections both proactively and reactively.


Research has shown that many individuals suffering from CRS exhibit decreased nitric oxide concentrations in their sinuses. Nitric oxide is a potent and natural antimicrobial molecule that healthy individuals produce at high levels in their sinuses as a defense mechanism.

NOTA Laboratories has multiple therapies in development, delivered via topical nasal treatment, that promote an increased nitric oxide presence in the sinuses. Increasing levels of NO help disperse microbial biofilms within the respiratory tract.  Such biofilms are resistant to conventional antibiotic therapy. Use of additional nitric oxide, therefore, can be leveraged in conjunction with traditional antibiotics to promote more effective treatment of said disorders.  


Beyond CRS, NOTA’s technologies can also be applied for treatment of other disorders which are associated with frequent infections in the respiratory tract, including chronic obstructive pulmonary disorder (COPD) and cystic fibrosis (CF).

For Investigational Use Only. Product is not commercially available.